The number of individuals being employed by Big Pharma has decreased over the past decade due to mergers, acquisitions and fiscal restraints. Very probably, the number of medicinal chemists employed by big Pharma in the UK has dropped by a third in this period. This article deals with this issue and how GSK has approached it by producing novel training programmes and attracting and retaining top chemistry talent.